Kalobios Pharmaceuticals Inc : Kalobios Pharmaceuticals Inc - "expect to have an FDA meeting to confirm regulatory pathway for benznidazole in treatment of Chagas disease" . Kalobios Pharmaceuticals Inc - to continue enrolling patients in company's ongoing phase 1 study of lenzilumab for chronic myelomonocytic leukemia . Kalobios Pharmaceuticals Inc - to explore partnering other proprietary monoclonal antibodies (MABS), such as ifabotuzumab .Says work on benznidazole program has accelerated since co acquired rights in June 2016.
Basilea Pharmaceutica AG :Expands oncology drug candidate BAl101553 clinical phase 1/2a oral study to include glioblastoma patients.
Neuron Bio SA :Says receives patent in Mexico for its NST0037 compound for neurodegenerative diseases.
Anhui Anke Biotechnology Group Co Ltd <300009.SZ> :Says it sets up a med lab as wholly-owned subsidiary in Hefei city with investment of 23 million yuan.
iNtRON Biotechnology Inc <048530.KQ> : Says it received patent on Nov. 10, for novel lactococcus garvieae bacteriophage lac-gap-1 and its use for preventing proliferation of lactococcus garvieae .Patent application number is 10-2015-0008012.
Targovax ASA : Has been granted European patent for oncos platform lead product, Oncos-102 .Composition of matter patent protects Targovax's lead product from its oncos platform, oncolytic viral product oncos-102 and expires in 2029.
Biocon Ltd :Biocon Ltd says Mylan and Biocon announce U.S. FDA submission for proposed biosimilar trastuzumab.
ilShinBiobase Co Ltd <068330.KQ> :Says it received patent on Nov. 4, for freeze dryer(containing loading and unloading system which can automatically supply or produce pharmaceutical vial and materials).
Factor Therapeutics Ltd : Received a notice of removal of full clinical hold from U.S. Food And Drug Administration .Is now permitted to proceed with its clinical trial.